This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Preview: Ingevity Corporation (NGVT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ingevity to Gain From Capa Buyout & Regulation-driven Demand
by Zacks Equity Research
While Ingevity (NGVT) is exposed to cost pressures, and weakness in industrial specialties and oilfield applications, it should gain from the Capa acquisition.
Here's Why You Should Hold Onto Ingevity (NGVT) Stock Now
by Zacks Equity Research
Let's find out why specialty chemicals and materials maker Ingevity (NGVT) is worth retaining at the moment.
Ingevity Provides Update in Response to Coronavirus Outbreak
by Zacks Equity Research
Ingevity's (NGVT) first quarter is going better than anticipated despite modest headwinds from the coronavirus outbreak.
Coronavirus, Tariffs Mar Chemical Specialty Industry Outlook
by Anindya Barman
Weak demand and raw material supply disruptions due to coronavirus as well as hefty trade tariffs pose as headwinds to the chemical specialty industry.
Why Is Ingevity Corporation (NGVT) Down 23.9% Since Last Earnings Report?
by Zacks Equity Research
Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ingevity (NGVT) Authorizes Share Repurchase Worth $500M
by Zacks Equity Research
Ingevity's (NGVT) new authorization provides it with the flexibility to be opportunistic through 2020.
New Strong Sell Stocks for February 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Ingevity (NGVT) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
While Ingevity (NGVT) faced challenges from continued macroeconomic pressure in the fourth quarter, it gained from growth in end-use applications.
Ingevity Corporation (NGVT) Q4 Earnings Beat Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 12.24% and -0.24%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Ingevity Corporation (NGVT) Up 2.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Near-Term Prospects Gloomy for Specialty Chemical Stocks
by Anindya Barman
Trade tariffs and raw material cost inflation pose as headwinds to the chemical specialty industry.
Ingevity's (NGVT) Earnings Top Estimates in Q3, Sales Miss
by Zacks Equity Research
While Ingevity (NGVT) faced challenges from weak market conditions in Q3, it gained from the Capa caprolactone acquisition.
Ingevity Corporation (NGVT) Q3 Earnings Beat Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 2.82% and -1.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Ingevity Corporation (NGVT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXTA vs. NGVT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AXTA vs. NGVT: Which Stock Is the Better Value Option?
Ingevity Corporation (NGVT) Down 20.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ICL or NGVT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?
ICL vs. NGVT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?
Ingevity's (NGVT) Earnings Beat Estimates in Q2, Sales Lag
by Zacks Equity Research
Ingevity (NGVT) gains from inorganic and organic growth strategy in Q2. The company reaffirms guidance for 2019.
Ingevity Corporation (NGVT) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 0.74% and -3.52%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Ingevity Corporation (NGVT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICL vs. NGVT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?
Ingevity (NGVT) Up 20% in a Year: What's Driving the Stock?
by Zacks Equity Research
Let's take a look into the factors that are working in Ingevity's (NGVT) favor.
ICL or NGVT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?